AUG 07, 2018 8:30 PM PDT

Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients

WRITTEN BY: Mauri Brueggeman

In June 2018, a new first of its kind drug class for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was approved by the Food and Drug Administration in the United States.  The target of this new drug class is Bcl-2, which is an apoptotic, or programmed cell death, regulator.  Bcl-2 controls cell death through mitochondrial membrane permeability mechanisms with caspases.  Bcl-2 is located on chromosome 18, and is considered an oncogene; this sequence can, and is, involved in translocations or mutations resulting in deregulation of expression in tumorigenesis.  Tumor cells must survive inhospitable conditions including hypoxia and loss of nutrient supply when they become advanced enough; each of these contribute to tumor cell damage susceptibility and apoptosis.  Tumor cells must adapt by gaining mutations that inhibit that apoptotic process which is what happens with Bcl-2 mutations. 

Bcl-2 family members, there are reported to be about 20 total related proteins, act to create protein channels or pores within the mitochondrial membrane allowing the release of factors like Cytochrome C.  These factors are intermediaries as part of one apoptotic pathway.  When Bcl-2 expression is affected by mutation, these factors cannot be released as a part of the apoptosis mechanism of the cell.

In mutated lymphocytic cells, there is high level of expression of proapoptotic proteins at the ready but they are stuck waiting by the blocked Bcl-2 pathway.  Patients with these primed mutated lymphocytes, like those with CLL, readily die when another apoptotic agent outside of that Bcl-2 mediated pathway is introduced in conjunction with this new drug class. 

Additional investigations are being made using Bcl-2 targeted drugs for other conditions like Multiple Myeloma (MM), which does not involve an altered chromosome 18; MM cells are plasma cells with a translocation between chromosomes 11 and 14.  However, one group of researchers published their investigation in Leukemia on August 3, 2018.  MM patients have overexpression of anti-apoptotic proteins like Bcl-2; they found that combination therapy which included venetoclax, the Bcl-2 targeted drug approved by the FDA in June, had a promising response rate in relapsed myeloma patients.  This type of pretreated myeloma patient has few options for disease free survival long term.  This new approach may prove to be clinically relevant in the near future after further research is conducted.  

Sources: Leukemia, Blood, FDA, BBA Molecular Cell Research,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 18, 2019
Genetics & Genomics
NOV 18, 2019
Evaluating the Genetic Damage Caused by Cancer Treatments
Now that we know more about the impact of some cancer treatments, they can be applied optimally....
NOV 20, 2019
Genetics & Genomics
NOV 20, 2019
Mining 'Junk' DNA for New Cancer Therapeutics
There are vast portions of the genome that don't code for protein, but researchers are learning more about how important they are....
DEC 21, 2019
Cancer
DEC 21, 2019
Processed meats containing nitrites linked to cancer
Since 2015, when the World Health Organization (WHO) classified processed meats as Group 1 carcinogens, science has supported the idea that these foods pos...
JAN 13, 2020
Cell & Molecular Biology
JAN 13, 2020
Disrupting Leukemia's Deadly Reliance on Vitamin B6
Acute Myeloid Leukemia is a cancer of the blood that starts in the bone marrow, where the stem cells that produce blood cells reside, and rapidly moves to the blood....
JAN 18, 2020
Cancer
JAN 18, 2020
What's the deal with turmeric?
Have you fallen for the turmeric craze? That little orange root that yellows your fingers when you peel it has become very popular recently for its medicin...
JAN 24, 2020
Immunology
JAN 24, 2020
Immune "Recycling" Could Improve Cancer Immunotherapy
A natural housekeeping function performed by many cells of the human body, including those in the immune system, is under intense scrutiny for its potentia...
Loading Comments...